Immutep To Present New Phase IIb Data In PD-L1 Negative Head And Neck Cancer At ESMO Immuno-Oncology 2024
Immutep To Present New Phase IIb Data In PD-L1 Negative Head And Neck Cancer At ESMO Immuno-Oncology 2024
Immutep将在2024年ESMO免疫肿瘤学大会上发布PD-L1阴性头颈癌新的IIb期数据。
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression (CPS <1) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland.
Immutep有限公司（ASX：IMm，纳斯达克：IMMP）（"Immutep"或"公司"），一家临床阶段的生物技术公司，正在开发用于癌症和自身免疫性疾病的新型LAG-3免疫疗法，今天宣布将在瑞士日内瓦举行的2024年欧洲医学肿瘤学协会免疫肿瘤学（ESMO I-O）大会上，就阴性PD-L1表达（CPS
资讯热榜
更新时间